146 related articles for article (PubMed ID: 24602192)
21. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
22. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
Cassius C; Pages C; Roux J; Lhote R; Lavocat R; Réa D; Bagot M; Mourah S; Battistella M; Lebbé C; Dumaz N
J Invest Dermatol; 2016 Jun; 136(6):1302-1305. PubMed ID: 26854489
[No Abstract] [Full Text] [Related]
23. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
Boudewijns S; Gerritsen WR; Koornstra RH
BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
[TBL] [Abstract][Full Text] [Related]
24. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients.
Launay-Vacher V; Zimner-Rapuch S; Poulalhon N; Fraisse T; Garrigue V; Gosselin M; Amet S; Janus N; Deray G
Cancer; 2014 Jul; 120(14):2158-63. PubMed ID: 24737576
[TBL] [Abstract][Full Text] [Related]
25. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
[TBL] [Abstract][Full Text] [Related]
27. RASopathic alopecia: hair changes associated with vemurafenib therapy.
Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
[No Abstract] [Full Text] [Related]
28. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
29. Vasculitis and panniculitis associated with vemurafenib.
Novoa RA; Honda K; Koon HB; Gerstenblith MR
J Am Acad Dermatol; 2012 Dec; 67(6):e271-2. PubMed ID: 23158633
[No Abstract] [Full Text] [Related]
30. Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma.
Trappe R; Budde U; Zimmermann H
Thromb Haemost; 2012 Oct; 108(4):798-800. PubMed ID: 22918265
[No Abstract] [Full Text] [Related]
31. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
Sabatier-Vincent M; Charles J; Pinel N; Challende I; Claeys A; Leccia MT
Ann Dermatol Venereol; 2014 Nov; 141(11):689-93. PubMed ID: 25442474
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
33. Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
Sinha R; Larkin J; Fearfield L
Br J Dermatol; 2015 Apr; 172(4):1135-6. PubMed ID: 25234953
[No Abstract] [Full Text] [Related]
34. Eccrine squamous syringometaplasia in sites of radiation recall secondary to vemurafenib therapy for BRAF-mutated carcinoma.
Moioli EK; Ligtenberg KG; Kenkare S; Shea CR; Soltani K
J Dermatol; 2016 Oct; 43(10):1233-1234. PubMed ID: 27094584
[No Abstract] [Full Text] [Related]
35. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Heakal Y; Kester M; Savage S
Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
37. Vemurafenib in melanoma.
Shaw HM; Nathan PD
Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
[TBL] [Abstract][Full Text] [Related]
38. Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infection.
Sondermann W; Griewank KG; Schilling B; Livingstone E; Leyh JC; Rompoti N; Cosgarea I; Schimming T; Schadendorf D; Zimmer L; Hillen U
PLoS One; 2015; 10(4):e0124590. PubMed ID: 25897843
[TBL] [Abstract][Full Text] [Related]
39. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
40. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
